** Shares of TG Therapeutics TGTX.O rise 4.3% to $38.2 premarket

** Co says its experimental subcutaneous formulation of multiple sclerosis drug, Briumvi, showed favorable safety and drug exposure in an early-stage study

** Study showed under-the-skin version of the therapy achieved sustained drug levels and was generally well tolerated compared with the approved intravenous formulation - TGTX

** No serious injection-site reactions and no new safety signals were observed, TGTX says

** Briumvi is currently approved in the United States for treating adults with relapsing forms of multiple sclerosis

** Co says a late-stage study comparing subcutaneous and IV Briumvi in patients with relapsing multiple sclerosis has completed enrolment, with results expected in late 2026 or early 2027

** We believe TG's Briumvi has the attractive potential to become the subQ of choice in the CD20 (marker on B cells) market - J.P. Morgan

** Up to last close, stock up 22.9% YTD